Tags : study

Clinical Trials

Eli Lilly Reports Results of Bamlanivimab (LY-CoV555) in P-III BLAZE-2

Shots: The P-III BLAZE-2 COVID-19 prevention trial involves assessing bamlanivimab (4,200mg) vs PBO in residents and staff at skilled nursing and assisted living facilities. The 965 &132 COVID-19 negative & positive participants were included in the analysis of 1EPS & 2EPs for assessing prevention & in exploratory analyses respectively The results demonstrated an 80% reduction […]Read More

Clinical Trials

Nektar Therapeutics Presents Preclinical Data of NKTR-255 in P-Ib/II Study

Shots: Nektar presents two nonclinical data presentations for NKTR-255 at the 62nd ASH Annual Meeting, which include an oral presentation of translational research studies conducted in collaboration with researchers from Dana-Farber Cancer Center NKTR-255 is being tested in a P-Ib/II study as monothx. & in combination with rituximab or daratumumab in patients with MM & […]Read More

Clinical Trials

Kite Reports Results of Yescarta in P-II ZUMA-5 Study for

Shots: The P-II ZUMA-5 study involves assessing Yescarta (axicabtagene ciloleucel) in patients with r/r iNHL after at least 2L of systemic therapy. After a single infusion of Yescarta, 92% of patients responded, including 76% of patients achieving a CR @median follow-up of 17.5 mos., results presented at ASH The data supports the US FDA’s acceptance […]Read More